GlassScriptPhysician profile
Aimee Coscarart
NPI 1699195958
$14,935.31
in general payments reported to CMS, 2019-2025
18 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $207 · 2024: $1,313 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,425 · Food and Beverage: $3,780 · Travel and Lodging: $1,088 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,425.00 |
| Food and Beverage | $3,779.58 |
| Travel and Lodging | $1,088.33 |
| Education | $310.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $10,873.01 | 2024-2025 | Sotyktu |
| Abbvie INC. | $1,025.58 | 2024-2025 | |
| Janssen Biotech, INC. | $476.82 | 2024-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $414.45 | 2021-2025 | |
| Hill Dermaceuticals, INC. | $351.69 | 2025 | Tolak |
| Regeneron Healthcare Solutions, INC. | $323.60 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $309.39 | 2022-2025 | |
| Leo Pharma INC. | $304.26 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $194.83 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $170.89 | 2025 | Nemluvio |
| Lilly USA, LLC | $153.38 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $87.92 | 2022-2025 | |
| Incyte Corporation | $44.97 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $35.15 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $26.82 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $21.48 | 2025 | Neo-Synalar |
| Organon LLC | $21.08 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Coscarart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.